As an attending hematopathologist I am involved in diagnostic work up and follow up after therapy of patients diagnosed with hematologic malignancies including AML, ALL, MDS and MDS/MPN. I am interested in understanding the pathogenesis of hematopoietic tumors and how specific events required for leukemic transformation can be targeted for therapy. In addition, as part of collaborative research projects I have been involved in the analyses of mice in models of normal and malignant hematopoiesis.
Department of Pathology, Univeristy of Chicago
Chicago
Fellowship - Hematopathology
2008
Department of Pathology, Univeristy of Chicago
Chicago
Residency - Clinical Pathology
2007
Ben May Department of Cancer Research, University of Chicago
Chicago
Post Doctoral Fellowship - Cancer Biology, Normal and Malignant Hematopoiesis
2004
INSERM U517, University of Burgundy
Dijon, France
Post Doctoral Fellowship - Cancer Biology, Apoptosis
2002
All India Institute of Medical Sciences
New Delhi, India
PhD - Hematology
2000
Motilal Nehru Medical College
Allahabad, India
MBBS - Medicine
1992
Malignant progression of pre-leukemic disorders.
Malignant progression of pre-leukemic disorders. Blood. 2024 Mar 18.
PMID: 38498034
PHF6 suppresses self-renewal of leukemic stem cells in AML.
PHF6 suppresses self-renewal of leukemic stem cells in AML. bioRxiv. 2024 Jan 18.
PMID: 38260439
Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults.
Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults. Blood Adv. 2024 01 09; 8(1):164-171.
PMID: 38039510
Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis.
Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis. Blood Cancer Discov. 2023 Dec 27.
PMID: 38150184
Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors.
Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors. Br J Haematol. 2023 Dec 10.
PMID: 38073116
Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults.
Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults. Blood Adv. 2023 Dec 01.
PMID: 38039510
Microbiota may affect the tumor type but not overall tumor development in two models of heritable cancer.
Microbiota may affect the tumor type but not overall tumor development in two models of heritable cancer. bioRxiv. 2023 Oct 12.
PMID: 37873087
Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors.
Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors. Haematologica. 2023 08 01; 108(8):2234-2239.
PMID: 36655425
Gata1s mutant mice display persistent defects in the erythroid lineage.
Gata1s mutant mice display persistent defects in the erythroid lineage. Blood Adv. 2023 07 11; 7(13):3253-3264.
PMID: 36350717
The Times, They Are A-Changing: The Impact of Next-Generation Sequencing on Diagnosis, Classification, and Prognostication of Myeloid Malignancies With Focus on Myelodysplastic Syndrome, AML, and Germline Predisposition.
The Times, They Are A-Changing: The Impact of Next-Generation Sequencing on Diagnosis, Classification, and Prognostication of Myeloid Malignancies With Focus on Myelodysplastic Syndrome, AML, and Germline Predisposition. Am Soc Clin Oncol Educ Book. 2023 Jun; 43:e390026.
PMID: 37307513